The role of immune checkpoint inhibitors in the treatment sequence of advanced gastric or gastro-esophageal junction cancer: A systematic review and meta-analysis of randomized trials

被引：17

作者：

Dubois, Marco ^{[1
,2
]}

Liscia, Nicole ^{[3
]}

Brunetti, Oronzo ^{[4
,5
]}

Ziranu, Pina ^{[1
,2
]}

Lai, Eleonora ^{[1
,2
]}

Argentiero, Antonella ^{[4
,5
]}

Mazza, Elena ^{[3
]}

Cascinu, Stefano ^{[3
]}

Silvestris, Nicola ^{[4
,5
]}

Casadei-Gardini, Andrea ^{[3
]}

Scartozzi, Mario ^{[1
,2
]}

机构：

[1] Univ Hosp, Med Oncol Unit, Cagliari, Italy

[2] Univ Cagliari, Cagliari, Italy

[3] Univ Vita Salute, San Raffaele Hosp IRCCS, Dept Med Oncol, I-20019 Milan, Italy

[4] IRCCS Ist Tumori Giovanni Paolo II Bari, I-70124 Bari, Italy

[5] Univ Bari Aldo Moro, Dept Biomed Sci & Human Oncol, I-70124 Bari, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2022年 / 173卷

关键词：

Immunotherapy; Immune checkpoint inhibitors; Chemotherapy; Advanced gastric cancer; Gastroesophageal-junction cancer; Immune checkpoint inhibitors chemotherapy; association; CHEMOTHERAPY; NIVOLUMAB;

D O I：

10.1016/j.critrevonc.2022.103674

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: This study aimed to clarify the current knowledge on the use of immunotherapy in patients with advanced gastric(G)/gastroesophageal(GEJ) cancers.& nbsp;Materials and metbods: A meta-analysis was done to evaluate the efficacy of immune checkpoint inhibitors(ICIs) in G/GEJ cancer both in the unselected population and in that stratified for combined positive score (CPS)>= 1 and >= 10 patients.& nbsp;Results: In the unselected population the result showed 21%(P < 0.00001), and 29%(P < 0.00001) reduction of death and progression risk for patients treated with ICIs compared without ICIs, while in CPS >= 1 and >= 10 populations, the result showed a death reduction of 19%(P = 0.001) and 33%(P < 0.00001) respectively, and, and 23% (P < 0.00001) and 43% (P < 0.00001) progression risk reduction respectively, for patients treated with and without ICIs.& nbsp;Conclusion: overall survival(OS) and progression free survival(PFS) data obtained in our meta-analysis, are in favor to use ICIs in association with standard first line chemotherapy for G/GEJ cancer patients regardless to CPS status

引用

页数：8

共 31 条

[1] Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin:: A study of the arbeitsgemeinschaft internistische onkologie [J].

Al-Batran, Salah-Eddin ;

Hartmann, Joerg Thomas ;

Probst, Stephan ;

Schmalenberg, Harald ;

Hollerbach, Stephan ;

Hofheinz, Ralf ;

Rethwisch, Volker ;

Seipelt, Gernot ;

Homann, Nils ;

Wilhelm, Gerhard ;

Schuch, Gunter ;

Stoehlmacher, Jan ;

Derigs, Hans Guenter ;

Hegewisch-Becker, Susanna ;

Grossmann, Johannes ;

Pauligk, Claudia ;

Atmaca, Akin ;

Bokemeyer, Carsten ;

Knuth, Alexander ;

Jaeger, Elke .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (09) :1435-1442

[2] Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory [J].

Arnold, Melina ;

Karim-Kos, Henrike E. ;

Coebergh, Jan Willem ;

Byrnes, Graham ;

Antilla, Ahti ;

Ferlay, Jacques ;

Renehan, Andrew G. ;

Forman, David ;

Soerjomataram, Isabelle .

EUROPEAN JOURNAL OF CANCER, 2015, 51 (09) :1164-1187

[3] Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 [J].

Bang, Y. -J. ;

Ruiz, E. Yanez ;

Van Cutsem, E. ;

Lee, K. -W. ;

Wyrwicz, L. ;

Schenker, M. ;

Alsina, M. ;

Ryu, M. -H. ;

Chung, H. -C. ;

Evesque, L. ;

Al-Batran, S. -E. ;

Park, S. H. ;

Lichinitser, M. ;

Boku, N. ;

Moehler, M. H. ;

Hong, J. ;

Xiong, H. ;

Hallwachs, R. ;

Conti, I. ;

Taieb, J. .

ANNALS OF ONCOLOGY, 2018, 29 (10) :2052-2060

[4]

Bang Y.J., 2010

[5] Comprehensive molecular characterization of gastric adenocarcinoma [J].

Bass, Adam J. ;

Thorsson, Vesteinn ;

Shmulevich, Ilya ;

Reynolds, Sheila M. ;

Miller, Michael ;

Bernard, Brady ;

Hinoue, Toshinori ;

Laird, Peter W. ;

Curtis, Christina ;

Shen, Hui ;

Weisenberger, Daniel J. ;

Schultz, Nikolaus ;

Shen, Ronglai ;

Weinhold, Nils ;

Keiser, David P. ;

Bowlby, Reanne ;

Sipahimalani, Payal ;

Cherniack, Andrew D. ;

Getz, Gad ;

Liu, Yingchun ;

Noble, Michael S. ;

Pedamallu, Chandra ;

Sougnez, Carrie ;

Taylor-Weiner, Amaro ;

Akbani, Rehan ;

Lee, Ju-Seog ;

Liu, Wenbin ;

Mills, Gordon B. ;

Yang, Da ;

Zhang, Wei ;

Pantazi, Angeliki ;

Parfenov, Michael ;

Gulley, Margaret ;

Piazuelo, M. Blanca ;

Schneider, Barbara G. ;

Kim, Jihun ;

Boussioutas, Alex ;

Sheth, Margi ;

Demchok, John A. ;

Rabkin, Charles S. ;

Willis, Joseph E. ;

Ng, Sam ;

Garman, Katherine ;

Beer, David G. ;

Pennathur, Arjun ;

Raphael, Benjamin J. ;

Wu, Hsin-Ta ;

Odze, Robert ;

Kim, Hark K. ;

Bowen, Jay .

NATURE, 2014, 513 (7517) :202-209

[6] PD-L1 is an independent prognostic predictor in gastric cancer of Western patients [J].

Boeger, Christine ;

Behrens, Hans-Michael ;

Mathiak, Micaela ;

Krueger, Sandra ;

Kalthoff, Holger ;

Roecken, Christoph .

ONCOTARGET, 2016, 7 (17) :24269-24283

[7]

Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]

[8] The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review [J].

Chen, Ke ;

Wang, Xiao ;

Yang, Liu ;

Chen, Zheling .

CANCER CONTROL, 2021, 28

[9]

Chen L.T., 2020, GASTRIC CANCER, V23

[10]

Chung HC, 2020, J CLIN ONCOL, V38, pe16586, DOI [10.1200/JCO.2020.38.15_suppl.e16586, DOI 10.1200/JCO.2020.38.15_SUPPL.E16586, 10.1200/jco.2020.38.15_suppl.e16586]

← 1 2 3 4 →